Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of HR17031 Injection in Healthy Subjects
NCT05031871Phase 1Completed
- Sponsor
- Hengrui
- Start
- Sep 2021
- Primary completion
- Nov 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HR17031 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Hengrui. Primary endpoints: Maximum observed concentration, Area under the curve from time zero to last measurable concentration and 1 more. Started Sep 2021; status: completed.
02
Drugs
HR17031
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05031871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05031871.